FIELD: medicine.
SUBSTANCE: algerone is administered at a dose of 140-160 mcg subcutaneously once a week for 12 weeks. After this, vero-cladribine is administered at a dose of 8-10 mcg IV daily for 7 days.
EFFECT: clinico-hematologic remission in patients with hairy-cell leukosis.
3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DIAGNOSIS OF MYELODYSPLASTIC SYNDROME | 2017 |
|
RU2657840C1 |
DIAGNOSTIC TECHNIQUE FOR DRUG-INDUCED LIVER INJURY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2695021C1 |
METHOD FOR ENDOSCOPIC TREATMENT OF ESOPHAGEAL DIVERTICULUM | 2018 |
|
RU2701388C1 |
METHOD OF TREATMENT HEPATIC CIRRHOSIS OF VARIOUS ETIOLOGY | 2015 |
|
RU2593007C1 |
METHOD OF TREATING CHRONIC CONSTIPATION AND FUNCTIONAL ANOREXIA | 2013 |
|
RU2545988C1 |
METHOD FOR RECONSTRUCTION OF ORAL CAVITY DEFECTS IN CASE OF ORAL MUCOSA AND SUBMANDIBULAR CANCER MUCOSA | 2018 |
|
RU2706031C1 |
METHOD FOR PREVENTION OF POSTOPERATIVE PURULENT COMPLICATIONS IN PATIENTS WITH HEPATOPANCREATOBILIARY ZONE PATHOLOGY | 2019 |
|
RU2774421C2 |
METHOD FOR ENDOSCOPIC DISSECTION OF EPITHELIAL FORMATIONS OF THE DIGESTIVE TRACT | 2022 |
|
RU2790240C1 |
METHOD FOR PREVENTING TUBERCULOSIS IN INFLAMMATORY INTESTINAL DISEASES | 2018 |
|
RU2712943C1 |
METHOD OF THE TREATMENT OF POLYNEUROPATHY ASSOCIATED WITH GLUTEN-SENSITIVE CELIAC DISEASE | 2022 |
|
RU2800847C1 |
Authors
Dates
2018-04-04—Published
2017-06-07—Filed